Ocean Biomedical, Inc.(OCEA)Earnings, Financials & Key Ratios
OCEA•NASDAQ
$0.00
$8251 mkt cap·Price updated May 6, 2026
AboutOcean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island.Show more
- Revenue$0
- EBITDA$0+100.0%
- Net Income-$3M-683.8%
- EPS (Diluted)-0.12-153.2%
- ROE-98.81%-18408.4%
OCEA Key Insights
Ocean Biomedical, Inc. (OCEA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Weak Piotroski F-Score: 0/9
- ✗Weak momentum: RS Rating 3 (bottom 3%)
- ✗Shares diluted 44.6% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
OCEA Price & Volume
Ocean Biomedical, Inc. (OCEA) stock price & volume — 10-year historical chart
Loading chart...
OCEA Growth Metrics
Ocean Biomedical, Inc. (OCEA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM0.82%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM3.45%
Return on Capital
10 Years-1.68%
5 Years-1.68%
3 Years-1.68%
Last Year-
OCEA Peer Comparison
Ocean Biomedical, Inc. (OCEA) competitors in Drug Discovery and Antibody Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 KALA | 855.53K | 0.12 | -0.02 | -141.11% | -388.29% | 2.62 | ||
 AGEN | 137.4M | 3.89 | -1144.12 | 10.37% | 0.1% | |||
 TPVG | 225.54M | 5.57 | 4.57 | 36.55% | 13.09% | 1.33 | ||
 NUVB | 1.75B | 5.04 | -8.40 | 6.99% | -102.06% | -44.1% | 0.03 | |
 ADMA | 2.46B | 10.08 | 16.80 | 19.63% | 28.8% | 34.98% | 0.17 | |
 SNDX | 1.82B | 20.65 | -6.28 | 6.28% | -112.01% | -256.66% | 5.36 | |
 LUNG | 54.49M | 1.29 | -0.97 | 8.01% | -59.67% | -82.79% | 1.04 |
Compare OCEA vs Peers
Ocean Biomedical, Inc. (OCEA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
OCEA Income Statement
Ocean Biomedical, Inc. (OCEA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
| Gross Margin % | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - |
| Operating Expenses | 232K | 1.65M | 566.56K | 2.48M | 3.8M | 4.16M |
| OpEx % of Revenue | - | - | - | - | - | - |
| Selling, General & Admin | 197K | 1.6M | 28.41M | 2.48M | 3.77M | 4.14M |
| SG&A % of Revenue | - | - | - | - | - | - |
| Research & Development | 35K | 49K | 33.93M | 0 | 26K | 18K |
| R&D % of Revenue | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | -61.78M | 0 | 0 | 0 |
| Operating Income | -232K▲ 0% | -1.65M▼ 612.1% | -566.56K▲ 65.7% | -2.48M▼ 338.0% | 0▲ 100.0% | -363K▲ 0% |
| Operating Margin % | - | - | - | - | - | - |
| Operating Income Growth % | - | -612.07% | 65.7% | -338.02% | 100% | - |
| EBITDA | -60.14K | -1.45M | -330K | -957.74K | 0 | -28.97M |
| EBITDA Margin % | - | - | - | - | - | - |
| EBITDA Growth % | - | -2303.9% | 77.17% | -190.22% | 100% | -50.91% |
| D&A (Non-Cash Add-back) | 171.86K | 206.3K | 236.56K | 0 | 0 | 0 |
| EBIT | 0 | 0 | -564.11K | -957.74K | 0 | -28.97M |
| Net Interest Income | 0 | 0 | 2.45K | 1.52M | 0 | -1.75M |
| Interest Income | 0 | 0 | 2.45K | 1.52M | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 691 | -2.05M | 1.75M |
| Other Income/Expense | 0 | -1K | 2.45K | 1.52M | 0 | -24.18M |
| Pretax Income | -232K▲ 0% | -1.65M▼ 612.5% | -564.11K▲ 65.9% | -958.43K▼ 69.9% | -3.3M▼ 244.4% | -24.54M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | -3.3M |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 13.45% |
| Net Income | -232K▲ 0% | -1.65M▼ 612.5% | -62.34M▼ 3671.6% | 565.47K▲ 100.9% | -3.3M▼ 683.8% | -30.72M▲ 0% |
| Net Margin % | - | - | - | - | - | - |
| Net Income Growth % | - | -612.5% | -3671.57% | 100.91% | -683.76% | 0.82% |
| Net Income (Continuing) | -232K | -1.65M | -564.11K | -958.43K | -3.3M | -21.24M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.01▲ 0% | -0.08▼ 611.3% | -0.04▲ 47.9% | -0.05▼ 11.3% | -0.12▼ 153.2% | -1.12▲ 0% |
| EPS Growth % | - | -611.3% | 47.92% | -11.27% | -153.16% | 3.45% |
| EPS (Basic) | -0.01 | -0.08 | -0.04 | -0.05 | -0.12 | - |
| Diluted Shares Outstanding | 20.2M | 20.2M | 13.22M | 19.02M | 27.5M | 27.5M |
| Basic Shares Outstanding | 20.2M | 20.2M | 13.22M | 19.02M | 27.5M | 27.5M |
| Dividend Payout Ratio | - | - | - | - | - | - |
OCEA Balance Sheet
Ocean Biomedical, Inc. (OCEA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Total Current Assets | 0 | 386K | 1.55M | 467.99K | 812K | 1.49M |
| Cash & Short-Term Investments | 0 | 0 | 1.08M | 328.31K | 0 | 0 |
| Cash Only | 0 | 0 | 1.08M | 328.31K | 0 | 0 |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 50K | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 0 | 386K | 0 | 0 | 224K | 777K |
| Total Non-Current Assets | 0 | 0 | 107.1M | 110.44M | 90K | 90K |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 107.1M | 110.44M | 90K | 844K |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 0▲ 0% | 386K▲ 0% | 108.65M▲ 28048.3% | 110.91M▲ 2.1% | 902K▼ 99.2% | 1.58M▲ 0% |
| Asset Turnover | - | - | - | - | - | 0.00x |
| Asset Growth % | - | - | 28048.28% | 2.08% | -99.19% | -211.26% |
| Total Current Liabilities | 232K | 2.27M | 246.44K | 3.46M | 33.89M | 26.57M |
| Accounts Payable | 0 | 53K | 34.44K | 0 | 799K | 964K |
| Days Payables Outstanding | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 2.15M | 16.3M | 9.35M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | -232K | 0 | 0 | 0 | 1.09M | 198K |
| Current Ratio | - | 0.17x | 6.29x | 0.14x | 0.02x | 0.02x |
| Quick Ratio | - | 0.17x | 6.29x | 0.14x | 0.02x | 0.02x |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 53K | 3.15M | 3.15M | 64.63M | 67.41M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 64.63M | 261.47M |
| Total Liabilities | 232K | 2.27M | 3.4M | 6.61M | 98.52M | 93.98M |
| Total Debt | 0 | 0 | 0 | 2.15M | 16.3M | 9.35M |
| Net Debt | 0 | 0 | -60K | 1.82M | 16.3M | 9.35M |
| Debt / Equity | - | - | - | 0.02x | - | -0.10x |
| Debt / EBITDA | - | - | - | - | - | -0.32x |
| Net Debt / EBITDA | - | - | - | - | - | -0.32x |
| Interest Coverage | - | - | - | -3591.37x | - | -16.53x |
| Total Equity | -232K▲ 0% | -1.89M▼ 712.5% | 105.26M▲ 5683.9% | 104.3M▼ 0.9% | -97.62M▼ 193.6% | -92.4M▲ 0% |
| Equity Growth % | - | -712.5% | 5683.87% | -0.91% | -193.59% | -1063.82% |
| Book Value per Share | -0.01 | -0.09 | 7.96 | 5.48 | -3.55 | -3.36 |
| Total Shareholders' Equity | -232K | -1.89M | 105.26M | 104.3M | -97.62M | -92.4M |
| Common Stock | 0 | 0 | 107.1M | 110.44M | 0 | 0 |
| Retained Earnings | -232K | -1.89M | -564.11K | -2.77M | -205.53M | -213.78M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
OCEA Cash Flow Statement
Ocean Biomedical, Inc. (OCEA) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Cash from Operations | 0 | -64K | -1.05M | -747.3K | -4.18M | -4.18M |
| Operating CF Margin % | - | - | - | - | - | - |
| Operating CF Growth % | - | - | -1545.31% | 29.03% | -459.35% | -48.78% |
| Net Income | -232K | -1.65M | -62.34M | -958.43K | -9.48M | -30.72M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 56.55M | 0 | 745K | 931K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 0 | 0 | 0 | -1.52M | 3.51M | 25.54M |
| Working Capital Changes | 232K | 1.59M | 4.74M | 1.74M | 1.04M | 198K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 290.38K | 869K | 957K |
| Cash from Investing | 0 | 0 | -107.1M | -2.1M | 0 | 0 |
| Capital Expenditures | 0 | 0 | 0 | -3 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 3 | 0 | 0 |
| Cash from Financing | 0 | 64K | 1.11M | 2.1M | 3.4M | 4.31M |
| Debt Issued (Net) | 0 | 0 | 0 | 2.1M | 3.4M | 909K |
| Equity Issued (Net) | 0 | 0 | 1000K | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 64K | 96K | 0 | 0 | 3.4M |
| Net Change in Cash | 0▲ 0% | 0▲ 0% | 60K▲ 0% | -747.3K▼ 1345.5% | -780K▼ 4.4% | 258K▲ 0% |
| Free Cash Flow | 0▲ 0% | -64K▲ 0% | -1.05M▼ 1545.3% | -747.3K▲ 29.0% | -4.18M▼ 459.3% | -4.05M▲ 0% |
| FCF Margin % | - | - | - | - | - | - |
| FCF Growth % | - | - | -1545.31% | 29.03% | -459.35% | 44.22% |
| FCF per Share | - | -0.00 | -0.08 | -0.04 | -0.15 | -0.15 |
| FCF Conversion (FCF/Net Income) | - | 0.04x | 0.02x | -1.32x | 1.27x | 0.13x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
OCEA Key Ratios
Ocean Biomedical, Inc. (OCEA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2024 | TTM |
|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -120.62% | 0.54% | -98.81% | 32.26% |
| Return on Invested Capital (ROIC) | - | -0.83% | -1.77% | - | 0.33% |
| Debt / Equity | - | - | 0.02x | - | -0.10x |
| Interest Coverage | - | - | -3591.37x | - | -16.53x |
| FCF Conversion | 0.04x | 0.02x | -1.32x | 1.27x | 0.13x |
OCEA Frequently Asked Questions
Ocean Biomedical, Inc. (OCEA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Ocean Biomedical, Inc. (OCEA) grew revenue by 0.0% over the past year. Growth has been modest.
Ocean Biomedical, Inc. (OCEA) reported a net loss of $30.7M for fiscal year 2024.
Dividend & Returns
Ocean Biomedical, Inc. (OCEA) has a return on equity (ROE) of -98.8%. Negative ROE indicates the company is unprofitable.
Ocean Biomedical, Inc. (OCEA) had negative free cash flow of $4.1M in fiscal year 2024, likely due to heavy capital investments.
Explore More OCEA
Ocean Biomedical, Inc. (OCEA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates